Barbara A. Conley

Ado-trastuzumab emtansine (T-DM1) in patients with HER2 amplified tumors excluding breast and gastric/gastro-esophageal junction (GEJ) adenocarcinomas: Results from the NCI-MATCH Trial (EAY131) Sub-protocol Q.

S. Luoh, R. Gray, K. Flaherty, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and Trametinib in Patients With Tumors With BRAFV600E Mutations: Results of the NCI-MATCH Trial Subprotocol H.

R. Gray, K. Flaherty, L. Rubinstein, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.